MedTrace Logo

Study of Huperzine A Sustained-Release Tablets in Patients With Alzheimer's Disease

NCT01282619 · Status: UNKNOWN · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 390

Last updated 2011-01-25

No results posted yet for this study

Summary

The main purpose of this study is to evaluate the safety and efficacy of Huperzine A sustained release tablets in patients with mild to moderate Alzheimer's Disease.

Conditions

Interventions

DRUG

Huperzine A

Sustained-Release Tablet, 400µg once a day, 24 weeks

DRUG

huperzine A

Tablet, 200µg twice a day, 24 weeks

DRUG

Placebo

placebo orally twice a day

Sponsors & Collaborators

  • Shandong Luye Pharmaceutical Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-05-31
Primary Completion
2012-06-30
Completion
2012-06-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01282619 on ClinicalTrials.gov